Responding to news that the NHS will allow Avastin to be prescribed for age related wet macular degeneration, RPS President Ash Soni said:
“This is a landmark ruling and good news for patients and the NHS.
“Avastin is licensed as a cancer treatment in the UK because the manufacturer has not sought a licence for any other purpose.
“Avastin has been shown through real world evidence to be a safe and effective for treatment for age related wet macular degeneration. The additional bonus is that it saves the NHS a significant amount of money, which can then be used to help other patients.
“Patients should always be involved in decision-making around the medicines they take whenever possible.”